MedTrace Logo

TEsting METformin Against Cognitive Decline in HD

NCT04826692 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-25

No results posted yet for this study

Summary

Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease.

The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind treatment period and a follow-up visit (one month after the end of treatment).

Conditions

  • Huntington Disease

Interventions

DRUG

Metformin

Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)

DRUG

Placebo

425 mg twice daily (initial dose) and 850 twice daily (maximum dose)

Sponsors & Collaborators

  • Instituto de Investigacion Sanitaria La Fe

    lead OTHER

Principal Investigators

  • Carmen Peiró, Phd, MD · Instituto de Investigación Sanitaria La Fe

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2025-06-10
Completion
2025-06-10

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826692 on ClinicalTrials.gov